 Nanobiotix NASDAQ: NBTX, ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that its nanoparticles were able to shrink tumors in about 77 of patients in a small Phase 1 trial. NBTXR3 consists of crystalline nanoparticles that are delivered by intratumoral injections. 